Systematic review and meta-analysis of the association between complement component 3 and age-related macular degeneration: A HuGE review and meta-analysis

American Journal of Epidemiology

Volumn 173, Issue 12, 2011, Pages 1365-1369

  Thakkinstian, Ammarin ^a   McKay, Gareth J ^b   McEvoy, Mark ^c   Chakravarthy, Usha ^b   Chakrabarti, Subhabrata ^d   Silvestri, Giuliana ^b   Kaur, Inderjeet ^d   Li, Xiaoxin ^e   Attia, John ^c,f,g  

^a MAHIDOL UNIVERSITY   (Thailand)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d L V PRASAD EYE INSTITUTE   (India)

^e PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^f HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^g JOHN HUNTER HOSPITAL   (Australia)

Author keywords

complement component factor 3; epidemiology; genetic association studies; genetics; macular degeneration; meta analysis

Indexed keywords

COMPLEMENT COMPONENT C3;

AGE CLASS; EPIDEMIOLOGY; ETHNICITY; EYE DISEASE; GENE EXPRESSION; GENETICS; GENOTYPE; HEALTH RISK; HETEROGENEITY; META-ANALYSIS; POLYMORPHISM; RISK ASSESSMENT; VISION;

ALLELE; ASIAN; CAUCASIAN; DISEASE ASSOCIATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; META ANALYSIS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SYSTEMATIC REVIEW;

AGE FACTORS; ASIAN CONTINENTAL ANCESTRY GROUP; COMPLEMENT C3; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MACULAR DEGENERATION;

CAUCASUS;

EID: 79958789920     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr025     Document Type: Review

References (63)

1. Klein ML, Schultz DW, Edwards A, et al. Age-related macular degeneration. Clinical features in a large family and linkage to chromosome 1q. Arch Ophthalmol. 1998;116(8):1082-1088. (Pubitemid 29101833)
2. Mitchell P, SmithW, Attebo K, et al. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology. 1995;102(10):1450-1460.
3. Pang CP, Baum L, Chan WM, et al. The apolipoprotein E e4 allele is unlikely to be a major risk factor of age-related macular degeneration in Chinese. Ophthalmologica. 2000;214(4):289-291. (Pubitemid 30339158)
4. VanNewkirk MR, Nanjan MB, Wang JJ, et al. The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology. 2000;107(8):1593- 1600.
5. Evans J,Wormald R. Is the incidence of registrable age-related macular degeneration increasing? Br J Ophthalmol. 1996;80(1):9-14.
6. Schmidt S, Klaver C, Saunders A, et al. A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy. Ophthalmic Genet. 2002;23(4):209-223. (Pubitemid 36238065)
7. Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102(2):205-210.
8. Conley YP, Jakobsdottir J, Mah T, et al. CFH, ELOVL4, PLEKHA1, and LOC387715 genes and susceptibility to agerelated maculopathy: AREDS and CHS cohorts and metaanalyses. Hum Mol Genet. 2006;15(21):3206-3218. (Pubitemid 44605500)
9. Despriet DD, Klaver CC, Witteman JC, et al. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA. 2006;296(3): 301-309. (Pubitemid 44079314)
10. Kaur I, Katta S, Hussain A, et al. Variants in the 10q26 gene cluster (LOC387715 and HTRA1) exhibit enhanced risk of age-related macular degeneration along with CFH in Indian patients. Invest Ophthalmol Vis Sci. 2008;49(5):1771-1776.
11. Rivera A, Fisher SA, Fritsche LG, et al. Hypothetical LOC387715 is a second major susceptibility gene for agerelated macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet. 2005;14(21):3227-3236. (Pubitemid 41631297)
12. Thakkinstian A, Han P, McEvoy M, et al. Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration. Hum Mol Genet. 2006;15(18):2784-2790. (Pubitemid 44400405)
13. Farwick A, Dasch B, Weber BH, et al. Variations in five genes and the severity of age-related macular degeneration: results from the Muenster Aging and Retina Study. Eye (Lond). 2009;23(12):2238-2244.
14. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006;38(4):458-462.
15. Jakobsdottir J, Conley YP,Weeks DE, et al. C2 and CFB genes in age-related maculopathy and joint action with CFH and LOC387715 genes [electronic article]. PLoS One. 2008;3(5): e2199.
16. McKay GJ, Dasari S, Patterson CC, et al. Complement component 3: an assessment of association with AMD and analysis of gene-gene and gene-environment interactions in a Northern Irish cohort. Mol Vis. 2010;16:194-199.
17. Richardson AJ, Islam FM, Guymer RH, et al. Analysis of rare variants in the complement component 2 (C2) and factor B (BF) genes refines association for age-related macular degeneration (AMD). Invest Ophthalmol Vis Sci. 2009;50(2):540-543.
18. Spencer KL, Hauser MA, Olson LM, et al. Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration. Hum Mol Genet. 2007;16(16):1986-1992. (Pubitemid 47354881)
19. Kaur I, Katta S, Reddy RK, et al. The involvement of complement factor B and complement component C2 in an Indian cohort with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;51(1):59-63.
20. Bergeron-Sawitzke J, Gold B, Olsh A, et al. Multilocus analysis of age-related macular degeneration. Eur J Hum Genet. 2009;17(9):1190-1199.
21. Cui L, Zhou H, Yu J, et al. Noncoding variant in the complement factor H gene and risk of exudative age-related macular degeneration in a Chinese population. Invest Ophthalmol Vis Sci. 2010;51(2):1116-1120.
22. Despriet DD, van Duijn CM, Oostra BA, et al. Complement component C3 and risk of age-related macular degeneration. Ophthalmology. 2009;116(3):474e2- 480e2.
23. Edwards AO, Fridley BL, James KM, et al. Evaluation of clustering and genotype distribution for replication in genome wide association studies: the Age-Related Eye Disease Study [electronic article]. PLoS One. 2008;3(11):e3813.
24. Francis PJ, Hamon SC, Ott J, et al. Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss. J Med Genet. 2009;46(5):300-307.
25. Goto A, Akahori M, Okamoto H, et al. Genetic analysis of typical wet-type age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese population. J Ocul Biol Dis Infor. 2009;2(4):164-175.
26. Gu J, Pauer GJ, Yue X, et al. Assessing susceptibility to agerelated macular degeneration with proteomic and genomic biomarkers. Clinical Genomic and Proteomic AMD Study Group. Mol Cell Proteomics. 2009;8(6):1338-1349.
27. Park KH, Fridley BL, Ryu E, et al. Complement component 3 (C3) haplotypes and risk of advanced age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50(7):3386-3393.
28. Pei XT, Li XX, Bao YZ, et al. Association of C3 gene polymorphisms with neovascular age-related macular degeneration in a Chinese population. Curr Eye Res. 2009; 34(8):615-622.
29. Reynolds R, Hartnett ME, Atkinson JP, et al. Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci. 2009;50(12):5818-5827.
30. Scholl HP, Fleckenstein M, Fritsche LG, et al. CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD [electronic article]. PLoS One. 2009;4(10):e7418.
31. Scholl HP, Charbel Issa P, Walier M, et al. Systemic complement activation in age-related macular degeneration [electronic article]. PLoS One. 2008;3(7):e2593.
32. Seddon JM, Reynolds R, Maller J, et al. Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. Invest Ophthalmol Vis Sci. 2009;50(5): 2044-2053.
33. Seitsonen SP, Onkamo P, Peng G, et al. Multifactor effects and evidence of potential interaction between complement factor H Y402H and LOC387715 A69S in age-related macular degeneration [electronic article]. PLoS One. 2008;3(12):e3833.
34. Spencer KL, Olson LM, Anderson BM, et al. C3 R102G polymorphism increases risk of age-related macular degeneration. Hum Mol Genet. 2008;17(12):1821-1824. (Pubitemid 351791509)
35. Yates JR, Sepp T, Matharu BK, et al. Complement C3 variant and the risk of age-related macular degeneration. Genetic Factors in AMD Study Group. N Engl J Med. 2007; 357(6):553-561. (Pubitemid 47236280)
36. Single nucleotide polymorphism. Reference SNP(refSNP) cluster report: rs2230199. Bethesda, MD: National Center for Biotechnology Information, US National Library of Medicine; 2010. (http://www.ncbi.nlm.nih.gov/SNP/snp-ref. cgi?rs1/42230199).
37. Single nucleotide polymorphism. Reference SNP(refSNP) cluster report: rs1047286. Bethesda, MD: National Center for Biotechnology Information, US National Library of Medicine; 2010. (http://www.ncbi.nlm.nih.gov/SNP/snp-ref. cgi?rs1/41047286).
38. Donoso LA, Kim D, Frost A, et al. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2006;51(2):137-152. (Pubitemid 43269939)
39. Sivaprasad S, Adewoyin T, Bailey TA, et al. Estimation of systemic complement C3 activity in age-related macular degeneration. Arch Ophthalmol. 2007;125(4):515-519. (Pubitemid 46596724)
40. Liu X, Zhao P, Tang S, et al. Association study of complement factor H, C2, CFB, and C3 and age-related macular degeneration in a Han Chinese population. Retina. 2010;30(8): 1177-1184.
41. Attia J, Thakkinstian A, D'Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol. 2003;56(4):297-303. (Pubitemid 36593307)
42. Thakkinstian A, McEvoy M, Minelli C, et al. Systematic review and meta-analysis of the association between b2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol. 2005;162(3):201-211. (Pubitemid 41373524)
43. Little J, Higgins J, eds. HuGE Review Handbook, Version 1.0. Cambridge, United Kingdom: HuGENet; 2006.
44. Ioannidis JP, Boffetta P, Little J, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol. 2008;37(1):120-132. (Pubitemid 351228620)
45. Thompson JR, Minelli C, Abrams KR, et al. Meta-analysis of genetic studies using Mendelian randomization-a multivariate approach. Stat Med. 2005;24(14):2241-2254. (Pubitemid 40960220)
46. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ. 1994;309(6965):1351-1355. (Pubitemid 24345976)
47. Thompson SG, Sharp SJ. Explaining heterogeneity in metaanalysis: a comparison of methods. Stat Med. 1999;18(20): 2693-2708. (Pubitemid 29481404)
48. Thompson SG, Smith TC, Sharp SJ. Investigating underlying risk as a source of heterogeneity in meta-analysis. Stat Med. 1997;16(23):2741-2758. (Pubitemid 27496919)
49. Minelli C, Thompson JR, Abrams KR, et al. The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol. 2005;34(6):1319-1328. (Pubitemid 41819539)
50. Trikalinos TA, Salanti G, Khoury MJ, et al. Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am J Epidemiol. 2006;163(4):300-309. (Pubitemid 43238423)
51. Hernández JL,Weir BS. A disequilibrium coefficient approach to Hardy-Weinberg testing. Biometrics. 1989;45(1):53-70. (Pubitemid 19109158)
52. Egger M, Davey Smith G, Schneider M, et al. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. (Pubitemid 27387172)
53. Egger M, Smith G, Altman D. Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd ed. London, United Kingdom: BMJ Publishing Group; 2001.
54. Moreno SG, Sutton AJ, Turner EH, et al. Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications [electronic article]. BMJ. 2009; 339:b2981.
55. Nüesch E, Trelle S, Reichenbach S, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study [electronic article]. BMJ. 2010;341:c3515.
56. Peters JL, Sutton AJ, Jones DR, et al. Contour-enhanced metaanalysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008; 61(10):991-996.
57. Palmer TM, Peter JL, Sutton AJ, et al. Contour-enhanced funnel plots in meta-analysis. STATA J. 2008;8(2):242-254.
58. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in metaanalysis. Biometrics. 2000;56(2):455-463. (Pubitemid 30422636)
59. Hayden KM, Zandi PP, Lyketsos CG, et al. Apolipoprotein E genotype and mortality: findings from the Cache County Study. Cache County Investigators. J Am Geriatr Soc. 2005;53(6):935-942. (Pubitemid 41647588)
60. Rossman MD, Thompson B, Frederick M, et al. HLADRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. ACCESS Group. Am J Hum Genet. 2003; 73(4):720-735. (Pubitemid 37271878)
61. STATA Statistical Software: Release 11.0. College Station, TX: StataCorp LP; 2009.
62. Spiegelhalter D, Thomas A, Best N, et al. WinBUGS User Manual. Cambridge, United Kingdom: MRC Biostatistics Unit, Institute of Public Health; 2007.
63. Thakkinstian A, McElduff P, D'Este C, et al. A method for meta-analysis of molecular association studies. Stat Med. 2005;24(9):1291-1306. (Pubitemid 40585169)